CA3003304A1 - Neoepitopes viraux et utilisations de ces derniers - Google Patents

Neoepitopes viraux et utilisations de ces derniers Download PDF

Info

Publication number
CA3003304A1
CA3003304A1 CA3003304A CA3003304A CA3003304A1 CA 3003304 A1 CA3003304 A1 CA 3003304A1 CA 3003304 A CA3003304 A CA 3003304A CA 3003304 A CA3003304 A CA 3003304A CA 3003304 A1 CA3003304 A1 CA 3003304A1
Authority
CA
Canada
Prior art keywords
patient
nucleic acid
hla
neoepitopes
neoepitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3003304A
Other languages
English (en)
Inventor
Andrew Nguyen
Stephen Charles BENZ
John Zachary Sanborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantomics LLC
Original Assignee
Nantomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics LLC filed Critical Nantomics LLC
Publication of CA3003304A1 publication Critical patent/CA3003304A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Primary Health Care (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Library & Information Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)

Abstract

L'invention concerne des traitements anticancéreux/antiviraux comprenant l'analyse de néoépitopes de l'ADN viral qui s'est intégré dans le génome dudit hôte, et la conception d'agents immunothérapeutiques dirigés contre ces néoépitopes.
CA3003304A 2015-10-12 2016-10-12 Neoepitopes viraux et utilisations de ces derniers Pending CA3003304A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240471P 2015-10-12 2015-10-12
US62/240,471 2015-10-12
PCT/US2016/056594 WO2017066290A1 (fr) 2015-10-12 2016-10-12 Néoépitopes viraux et utilisations de ces derniers

Publications (1)

Publication Number Publication Date
CA3003304A1 true CA3003304A1 (fr) 2017-04-20

Family

ID=57882798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003304A Pending CA3003304A1 (fr) 2015-10-12 2016-10-12 Neoepitopes viraux et utilisations de ces derniers

Country Status (11)

Country Link
US (3) US10339274B2 (fr)
EP (1) EP3362929B1 (fr)
JP (1) JP6991967B2 (fr)
KR (1) KR20180087248A (fr)
CN (1) CN108604257B (fr)
AU (1) AU2016338947B2 (fr)
CA (1) CA3003304A1 (fr)
HK (1) HK1258093A1 (fr)
IL (1) IL258682B (fr)
MX (1) MX2018004542A (fr)
WO (1) WO2017066290A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12080382B2 (en) 2015-10-12 2024-09-03 Nantomics, Llc Viral neoepitopes and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
US10776966B2 (en) * 2017-04-28 2020-09-15 Oracle International Corporation Graph processing system that allows flexible manipulation of edges and their properties during graph mutation
US20220108768A1 (en) * 2019-03-08 2022-04-07 Nantomics, Llc System and method for variant calling
KR102425492B1 (ko) * 2020-04-27 2022-07-26 한림대학교 산학협력단 Sars-cov-2 바이러스에 대한 에피토프 기반 펩타이드 백신의 개발 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579234B2 (ja) 2003-03-10 2010-11-10 エクスプレッション、パソロジー、インコーポレイテッド 組織病理学的に加工処理された生物サンプル、組織および細胞からの液体組織調製物
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
CA2735677A1 (fr) * 2008-08-22 2010-02-25 Novartis Ag Utilisation d'un inhibiteur de cox-2 pour le traitement d'un trouble dependant de cox-2 chez un patient qui ne porte pas d'alleles hla associes a une hepatotoxicite
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569633B1 (fr) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions et procédés d'identification de néoantigènes spécifiques à une tumeur
AU2011258875B2 (en) 2010-05-25 2016-05-05 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
DK2714071T3 (da) * 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
CA2842887C (fr) * 2011-08-12 2021-01-19 Oncotherapy Science, Inc. Peptides mphosph1 et vaccins les contenant
EP2758545B1 (fr) * 2011-09-23 2017-07-26 Oxford Nanopore Technologies Limited Analyse d'un polymère comprenant des unités de polymère
RS56773B1 (sr) * 2012-01-13 2018-04-30 Univ Wuerzburg J Maximilians Dvojna bipartitna funkcionalna komplementacija izazvana antigenom
CN104684577B (zh) * 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
WO2014012051A1 (fr) * 2012-07-12 2014-01-16 Persimmune, Inc. Vaccins anticancéreux personnalisés et thérapies cellulaires immunitaires adoptives
KR20210156320A (ko) * 2013-04-07 2021-12-24 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
CN103320522B (zh) * 2013-07-16 2016-03-30 深圳华大基因研究院 确定人宫颈癌样本基因组中hpv整合位点的方法和系统
JP2015035212A (ja) * 2013-07-29 2015-02-19 アジレント・テクノロジーズ・インクＡｇｉｌｅｎｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ターゲットシークエンシングパネルから変異を見つける方法
KR20190104164A (ko) 2013-09-26 2019-09-06 파이브3 제노믹스, 엘엘씨 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
RU2707530C2 (ru) * 2014-01-02 2019-11-27 Мемориал Слоан Кеттеринг Кэнсер Сентер Детерминанты ответа раковой опухоли на иммунотерапию
EP3302574A4 (fr) * 2015-05-26 2018-10-17 Advaxis, Inc. Immunothérapie à base de vecteurs d'administration personnalisés, et leurs utilisations
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
CN108604257B (zh) 2015-10-12 2022-12-13 南托米克斯有限责任公司 产生特异性免疫治疗组合物及其相关核酸构建体的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12080382B2 (en) 2015-10-12 2024-09-03 Nantomics, Llc Viral neoepitopes and uses thereof

Also Published As

Publication number Publication date
EP3362929B1 (fr) 2020-08-12
AU2016338947B2 (en) 2020-06-04
KR20180087248A (ko) 2018-08-01
CN108604257A (zh) 2018-09-28
US10339274B2 (en) 2019-07-02
AU2016338947A1 (en) 2018-05-10
HK1258093A1 (zh) 2019-11-01
US20240321392A1 (en) 2024-09-26
EP3362929A1 (fr) 2018-08-22
CN108604257B (zh) 2022-12-13
US20170032103A1 (en) 2017-02-02
US20190287656A1 (en) 2019-09-19
WO2017066290A1 (fr) 2017-04-20
JP2018536225A (ja) 2018-12-06
IL258682B (en) 2022-03-01
JP6991967B2 (ja) 2022-01-13
EP3362929A4 (fr) 2019-06-19
US12080382B2 (en) 2024-09-03
MX2018004542A (es) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2020200208B2 (en) Compositions and methods for viral cancer neoepitopes
US20220403007A1 (en) Cancer Neoepitopes
US11717564B2 (en) Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
US20240321392A1 (en) Viral Neoepitopes and Uses Thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210621

EEER Examination request

Effective date: 20210621

EEER Examination request

Effective date: 20210621

EEER Examination request

Effective date: 20210621

EEER Examination request

Effective date: 20210621

EEER Examination request

Effective date: 20210621

EEER Examination request

Effective date: 20210621